Explore 3 Stock Ideas & Industry Insights Download Free Report

Healthcare

Arcutis Biotherapeutics (NASDAQ:ARQT) Gains 9% on New Dermatology Data

Arcutis Biotherapeutics (NASDAQ:ARQT) shares traded sharply higher after the company presented new data on its ZORYVEFranchiseat the EADV Congress and the Fall Clinical Dermatology Conference. Arcutis Biotherapeutics is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for immune-mediated dermatological diseases, with …

Nitish Kishor | 09 October 2026

Astrana Health (NASDAQ:ASTH) Gains 5% on Earnings Beat Expectations

Astrana Health (NASDAQ:ASTH) shares closed higher, recovering from Thursday's 3.4% slide as healthcare stocks gained broadly, with the sector ETF up about 1.6% in afternoon trading. Astrana Health is a physician-centric, technology-enabled healthcare management company that operates an integrated, value-based care model across three …

Nitish Kishor | 09 October 2026

Azenta (NASDAQ:AZTA) Rises 5% Despite Governance Overhang and Lab Closures

Azenta (NASDAQ:AZTA) shares closed higher, rebounding alongside a broadly firmer healthcare sector even as the company continues to navigate a governance overhang and an ongoing restructuring. Azenta is a global life sciences company that provides solutions for the storage, management, and analysis of biological …

Nitish Kishor | 09 October 2026

Brookdale Senior Living (NYSE:BKD) Falls 7% as Occupancy Growth Cools

Brookdale Senior Living (NYSE:BKD) shares closed sharply lower after RBC said the company's September occupancy update showed cooling momentum. Brookdale Senior Living is the largest operator of senior living communities in the United States, operating independent living, assisted living, memory care, and continuing care …

Nitish Kishor | 09 October 2026

Caris Life Sciences (NASDAQ:CAI) Surges 8% on BofA Price Target Raise

Caris Life Sciences (NASDAQ:CAI) shares closed sharply higher after BofA Securities raised its price target on the stock to $35 from $23, a notable move above both the $26.50 consensus target and the $27.08 average analyst target. Caris Life Sciences is an AI-driven precision …

Nitish Kishor | 09 October 2026

Definium Therapeutics (NASDAQ:DFTX) Gains 8% on JPMorgan Coverage Initiation

Definium Therapeutics (NASDAQ:DFTX), formerly known as Mind Medicine, shares advanced after JPMorgan initiated coverage on the stock with an Overweight rating and an $84 price target, implying roughly 145% upside from the prior close. Definium Therapeutics is a late-stage clinical biopharmaceutical company applying scientific …

Nitish Kishor | 09 October 2026

Hims & Hers Health (NYSE:HIMS) Rebounds 10% After Prior Session's Selloff

Hims & Hers Health (NYSE:HIMS) shares closed sharply higher, rallying alongside a broader healthcare sector rebound and recovering a meaningful portion of the prior session's roughly 5% decline. Hims & Hers Health is a digital health platform that connects consumers with licensed medical professionals …

Nitish Kishor | 09 October 2026

Humana (NYSE:HUM) Shares Surge 11% as Star Ratings Jump Lifts 2028 Bonus Outlook

Humana (NYSE:HUM) shares closed sharply higher on October 9 after the company announced improved Centers for Medicare and Medicaid Services Star Ratings for 2027, with 95% of its Medicare Advantage members now enrolled in plans rated 4.0 stars or above, and 42% in plans …

Nitish Kishor | 09 October 2026

ImmunityBio (NASDAQ:IBRX) Rises 6% Ahead of Investor Symposium

ImmunityBio (NASDAQ:IBRX) shares closed higher, attracting speculative buying ahead of founder Patrick Soon-Shiong's fireside chat at an oncology investor symposium scheduled for October 16. ImmunityBio is a San Diego-based, commercial-stage immunotherapy company that develops next-generation therapies and vaccines to activate the innate and adaptive …

Nitish Kishor | 09 October 2026

Iovance Biotherapeutics (NASDAQ:IOVA) Rises 10% on Raised Revenue Guidance

Iovance Biotherapeutics (NASDAQ:IOVA) shares closed sharply higher after the company raised its 2026 revenue guidance to a range of $410 million to $420 million, up from a prior range of $350 million to $370 million. Iovance Biotherapeutics is a commercial-stage biotechnology company that develops …

Nitish Kishor | 09 October 2026
Support

Hi! How can we help you today?

Loading…